JP2020022505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020022505A5 JP2020022505A5 JP2019203285A JP2019203285A JP2020022505A5 JP 2020022505 A5 JP2020022505 A5 JP 2020022505A5 JP 2019203285 A JP2019203285 A JP 2019203285A JP 2019203285 A JP2019203285 A JP 2019203285A JP 2020022505 A5 JP2020022505 A5 JP 2020022505A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- virus
- specific
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 241000700605 Viruses Species 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 244000052613 viral pathogen Species 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 241000701022 Cytomegalovirus Species 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 208000007514 Herpes zoster Diseases 0.000 claims 3
- 241000701806 Human papillomavirus Species 0.000 claims 3
- 241000829111 Human polyomavirus 1 Species 0.000 claims 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000004043 responsiveness Effects 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022066435A JP2022089916A (ja) | 2011-12-12 | 2022-04-13 | Ｔ細胞増殖のためのプロセス |
| JP2023179166A JP2023174861A (ja) | 2011-12-12 | 2023-10-17 | Ｔ細胞増殖のためのプロセス |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1121308.9A GB201121308D0 (en) | 2011-12-12 | 2011-12-12 | Process |
| GB1121308.9 | 2011-12-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132663A Division JP6657145B2 (ja) | 2011-12-12 | 2017-07-06 | Ｔ細胞増殖のためのプロセス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066435A Division JP2022089916A (ja) | 2011-12-12 | 2022-04-13 | Ｔ細胞増殖のためのプロセス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020022505A JP2020022505A (ja) | 2020-02-13 |
| JP2020022505A5 true JP2020022505A5 (https=) | 2021-01-21 |
Family
ID=45560301
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546633A Active JP6203745B2 (ja) | 2011-12-12 | 2012-12-12 | Ｔ細胞増殖のためのプロセス |
| JP2014546634A Pending JP2015505852A (ja) | 2011-12-12 | 2012-12-12 | 動員ドナーからの治療用ｔ細胞生成物を用いる処置方法 |
| JP2017132663A Active JP6657145B2 (ja) | 2011-12-12 | 2017-07-06 | Ｔ細胞増殖のためのプロセス |
| JP2019203285A Withdrawn JP2020022505A (ja) | 2011-12-12 | 2019-11-08 | Ｔ細胞増殖のためのプロセス |
| JP2022066435A Pending JP2022089916A (ja) | 2011-12-12 | 2022-04-13 | Ｔ細胞増殖のためのプロセス |
| JP2023179166A Withdrawn JP2023174861A (ja) | 2011-12-12 | 2023-10-17 | Ｔ細胞増殖のためのプロセス |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546633A Active JP6203745B2 (ja) | 2011-12-12 | 2012-12-12 | Ｔ細胞増殖のためのプロセス |
| JP2014546634A Pending JP2015505852A (ja) | 2011-12-12 | 2012-12-12 | 動員ドナーからの治療用ｔ細胞生成物を用いる処置方法 |
| JP2017132663A Active JP6657145B2 (ja) | 2011-12-12 | 2017-07-06 | Ｔ細胞増殖のためのプロセス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066435A Pending JP2022089916A (ja) | 2011-12-12 | 2022-04-13 | Ｔ細胞増殖のためのプロセス |
| JP2023179166A Withdrawn JP2023174861A (ja) | 2011-12-12 | 2023-10-17 | Ｔ細胞増殖のためのプロセス |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20140341951A1 (https=) |
| EP (2) | EP2791163B2 (https=) |
| JP (6) | JP6203745B2 (https=) |
| AU (2) | AU2012351843B2 (https=) |
| ES (1) | ES2626492T5 (https=) |
| GB (1) | GB201121308D0 (https=) |
| HK (1) | HK1203219A1 (https=) |
| WO (2) | WO2013088148A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| CN104411819B (zh) * | 2012-06-11 | 2019-05-10 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| GB201509202D0 (en) * | 2015-05-28 | 2015-07-15 | Ge Healthcare Bio Sciences Ab | Semi-static cell culture |
| HK1254397A1 (zh) | 2015-06-26 | 2019-07-19 | 纪念斯隆-凯特林癌症中心 | 通过t细胞疗法治疗cmv视网膜炎的方法 |
| JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
| US11473059B2 (en) | 2015-10-22 | 2022-10-18 | Lucas Bio Co. Ltd. | Method for enrichment and expansion of virus antigen-specific T cells |
| US11248238B2 (en) | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| EP3368051B1 (en) | 2015-10-30 | 2026-04-15 | Children's National Medical Center | Generating hpv antigen-specific t cells from a naive t cell population |
| US20190032013A1 (en) * | 2016-01-29 | 2019-01-31 | Tract Therapeutics, Inc. | Immune cell selection, expansion, and use |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| CN109843921B (zh) | 2016-07-07 | 2023-05-26 | 艾欧凡斯生物治疗公司 | 程序性死亡1配体1(pd-l1)结合蛋白及其应用方法 |
| MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US11401507B2 (en) | 2016-11-17 | 2022-08-02 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| JOP20190224A1 (ar) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US10821134B2 (en) | 2017-05-17 | 2020-11-03 | Board Of Regents, The University Of Texas System | BK virus specific T cells |
| BR112019024556A2 (pt) | 2017-05-24 | 2020-06-23 | Novartis Ag | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer |
| EP3635097A1 (en) * | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US20210130779A1 (en) | 2018-04-27 | 2021-05-06 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) * | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| FR3082524B1 (fr) * | 2018-06-18 | 2022-03-25 | Univ Paris Sud | Methode de stratification du risque de nephropathie a bk-virus apres transplantation renale |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| AU2019375997A1 (en) | 2018-11-08 | 2021-06-03 | Neximmune, Inc. | T cell compositions with improved phenotypic properties |
| CN120172958A (zh) | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| US10772914B1 (en) | 2019-04-18 | 2020-09-15 | Baylor College Of Medicine | EBV-specific immune cells |
| US12516291B2 (en) | 2019-12-11 | 2026-01-06 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same |
| US12159700B2 (en) | 2020-04-22 | 2024-12-03 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| US11781100B2 (en) | 2020-12-03 | 2023-10-10 | Applied Materials, Inc. | All-in-one bioreactor for therapeutic cells manufacturing |
| US20240060044A1 (en) * | 2021-02-25 | 2024-02-22 | Senthilkumar NATESAN | A novel method of generating t cells from peripheral blood precursors and their uses thereof |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| EP4373919A1 (en) | 2021-07-18 | 2024-05-29 | Gamida-Cell Ltd. | Therapeutic nk cell populations |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| US20260092248A1 (en) * | 2022-09-15 | 2026-04-02 | Life Technologies Corporation | Bioreactors operable in static and dynamic modes and methods of use |
| WO2024145700A1 (pt) * | 2023-01-02 | 2024-07-11 | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein | Método de expansão de linfócitos vírus-específicos, composição e uso de uma composição |
| US20250144143A1 (en) * | 2023-11-06 | 2025-05-08 | Immunitybio, Inc. | Virally Educated T cells |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641628A (en) | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
| WO1994002156A1 (en) | 1992-07-16 | 1994-02-03 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate t cells |
| US6821778B1 (en) | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
| WO1995024217A1 (en) | 1994-03-08 | 1995-09-14 | Dana-Farber Cancer Institute | Methods for modulating t cell unresponsiveness |
| AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
| PT772624E (pt) | 1994-04-06 | 2001-03-30 | Immunex Corp | Interleucina-15 |
| PT804210E (pt) | 1994-05-16 | 2003-04-30 | Roche Diagnostics Gmbh | Processo de imunomodelacao por transferencia adoptiva de linfocitos t citotoxicos especificos de um antigenio |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| PT747481E (pt) | 1995-06-06 | 2002-05-31 | Organon Teknika Bv | Peptidos do virus de epstein-barr e anticorpos contra estes peptidos |
| FR2745185B1 (fr) | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
| US6699477B2 (en) | 1996-05-24 | 2004-03-02 | The Council Of The Queensland Institute Of Medical Research | EBV CTL epitopes |
| US5962318A (en) | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
| WO1998033888A1 (en) | 1997-01-31 | 1998-08-06 | Epimmune, Inc. | Peptides and peptide-loaded antigen presenting cells for the activation of ctl |
| US6528307B1 (en) | 1997-04-25 | 2003-03-04 | The Wistar Institute Of Anatomy And Biology | Cytolytic T-cell clones against colorectal carcinoma |
| US7951383B2 (en) | 1997-05-23 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated parainfluenza virus (PIV) vaccines |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| ATE428769T1 (de) | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| US20020155108A1 (en) | 1998-05-04 | 2002-10-24 | Biocrystal, Ltd. | Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells |
| WO2000050569A1 (en) | 1999-02-24 | 2000-08-31 | The Wistar Institute Of Anatomy And Biology | Method of modifying cytotoxic cells and uses thereof |
| US6828147B1 (en) | 1999-02-24 | 2004-12-07 | The Wistar Institute Of Anatomy And Biology | Method of modifying cytotoxic cells and uses thereof |
| US7005131B1 (en) | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
| US20150037297A1 (en) | 1999-08-30 | 2015-02-05 | David S Terman | Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors |
| AU2425801A (en) | 1999-11-24 | 2001-06-04 | Ernest G. Hope | Anti-angiogenic cellular agent for cancer therapy |
| DE10009341A1 (de) | 2000-02-22 | 2001-09-06 | Florian Kern | Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten |
| US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| DK2336187T3 (en) | 2000-06-19 | 2016-08-22 | Beth Israel Deaconess Medical Ct Inc | Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations |
| AU2001288863A1 (en) | 2000-09-15 | 2002-03-26 | Ortho-Mcneil Pharmaceutical, Inc. | Compositions and methods for inducing specific cytolytic t cell responses |
| EP1229043A1 (en) | 2001-01-30 | 2002-08-07 | Cyto-Barr B.V. | Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith |
| GB0107628D0 (en) | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
| US20040022761A1 (en) | 2001-05-11 | 2004-02-05 | Banchereau Jacques F | Compositions and methods for producing antigen-presenting cells |
| ATE438710T1 (de) | 2001-05-15 | 2009-08-15 | Ortho Mcneil Janssen Pharm | Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen |
| UA75429C2 (en) | 2001-09-28 | 2006-04-17 | Mowing blade | |
| EP1444330A1 (en) | 2001-11-07 | 2004-08-11 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| RU2313365C2 (ru) | 2001-11-29 | 2007-12-27 | Дандрит Байотек А/С | Фармацевтическая композиция для индукции иммунной реакции у человека |
| US20040096457A1 (en) | 2001-12-11 | 2004-05-20 | Huber Brigitte T | Treatment and prevention of ebv infection and ebv-associated disorders |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2004041849A1 (en) | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| AU2002953238A0 (en) | 2002-12-09 | 2003-01-02 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | In vitro immunization |
| IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| US20050221481A1 (en) | 2004-03-30 | 2005-10-06 | Istituto Superiore Di Sanita' | Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2 |
| US7785806B2 (en) | 2004-04-28 | 2010-08-31 | Vaxdesign Corporation | Method for determining the immunogenicity of an antigen |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US7785875B2 (en) | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
| US20060045883A1 (en) | 2004-08-26 | 2006-03-02 | Jeffrey Molldrem | Anti-cancer vaccines |
| JP4731867B2 (ja) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法 |
| WO2006099448A2 (en) | 2005-03-14 | 2006-09-21 | University Of Iowa Research Foundation | Accelerated cd8+ t-cell memory after dendritic cell vaccination |
| EP1712615A1 (en) | 2005-04-15 | 2006-10-18 | Txcell | In vitro production of a cell population using feeder cells |
| ES2334936T3 (es) | 2005-04-20 | 2010-03-17 | F. Hoffmann-La Roche Ag | Metodo de identificacion de epitopos relacionados con la inmunogenicidad en biofarmacos. |
| WO2006124412A2 (en) | 2005-05-11 | 2006-11-23 | The Trustees Of The University Of Pennsylvania | Methods for the rapid expansion of antigen specific t-cells |
| US20070003531A1 (en) | 2005-06-30 | 2007-01-04 | University Of Connecticut | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes |
| US20100035282A1 (en) | 2005-08-03 | 2010-02-11 | Maria Chiara Bonini | Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes |
| JP4824389B2 (ja) | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| JP5492418B2 (ja) | 2005-11-18 | 2014-05-14 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法 |
| PL1989544T3 (pl) | 2006-03-02 | 2012-01-31 | Antitope Ltd | Testy na komórkach T |
| US20070243549A1 (en) | 2006-04-12 | 2007-10-18 | Biocept, Inc. | Enrichment of circulating fetal dna |
| WO2008025992A2 (en) | 2006-09-01 | 2008-03-06 | Cambridge Enterprise Limited | Methods of expanding non-effector cd8 t-cell populations |
| EP2091961A4 (en) | 2006-11-22 | 2009-12-09 | Univ Arkansas | IMMUNOTHERAPY AGAINST CANCER WITH MULTIPPITOP-PEPTIDE-LOADED DENDRITIC CELLS |
| AU2007332869B2 (en) | 2006-12-07 | 2012-10-11 | Wilson Wolf Manufacturing, LLC | Highly efficient gas permeable devices and methods for culturing cells |
| DK2117571T3 (en) | 2006-12-08 | 2017-05-08 | Monopar Therapeutics Inc | Urokinase-type plasminogen activator receptor epitope |
| DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
| CA2700618A1 (en) | 2007-09-27 | 2009-04-02 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| US20100254958A1 (en) | 2007-10-24 | 2010-10-07 | Anne Letsch | Antigen-Specific T-Cell Preparations from Bone Marrow |
| JP2011502484A (ja) | 2007-11-01 | 2011-01-27 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用 |
| EP2065462A1 (en) | 2007-11-27 | 2009-06-03 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens |
| EP2321407A4 (en) | 2008-09-11 | 2012-07-18 | Univ Florida | SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS |
| CN101824400B (zh) | 2009-03-05 | 2012-08-08 | 中国科学院微生物研究所 | 一种放大增殖抗原特异性t细胞的方法 |
| EP3101122B1 (en) * | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| JP5833443B2 (ja) | 2009-08-29 | 2015-12-16 | 株式会社バイオメッドコア | 抗原特異的ｔ細胞誘導能測定法 |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| US8809050B2 (en) | 2009-12-08 | 2014-08-19 | Wilson Wolf Manufacturing | Methods of cell culture for adoptive cell therapy |
| BR112012029066A2 (pt) | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| US9114100B2 (en) | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
| EP2600890A1 (en) | 2010-08-04 | 2013-06-12 | Instituto Europeo di Oncologia S.r.l. | Method of antigen loading for immunotherapy |
| US8741642B2 (en) | 2010-10-22 | 2014-06-03 | Virginia Commonwealth University | Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects |
| EP2453243A1 (en) | 2010-11-11 | 2012-05-16 | Cosmo S.p.A. | Method for the diagnosis and/or follow up of the evolution of a tumor |
| US20130045491A1 (en) | 2011-07-19 | 2013-02-21 | Derya Unutmaz | Methods for activating t cells |
| AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| CN104769104A (zh) | 2011-12-12 | 2015-07-08 | 细胞药物有限公司 | 扩大t细胞的方法 |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
| HK1207667A1 (en) | 2012-05-08 | 2016-02-05 | Western University Of Health Sciences | Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations |
| US10357515B2 (en) | 2013-11-22 | 2019-07-23 | Cellectis | Method for generating batches of allogeneic T-cells with averaged potency |
| JP5870082B2 (ja) | 2013-12-19 | 2016-02-24 | 住友ゴム工業株式会社 | 重荷重用タイヤ |
| US20160341718A1 (en) | 2014-01-21 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for testing t cell priming efficacy in a subject |
| MY189857A (en) | 2014-11-05 | 2022-03-14 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line and donor thereof for adoptive cellular therapy |
| WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| IL294055A (en) | 2015-03-20 | 2022-08-01 | Childrens Nat Medical Ct | Generating virus or other antigen-specific t cells from a naive t cell population |
| HK1254397A1 (zh) | 2015-06-26 | 2019-07-19 | 纪念斯隆-凯特林癌症中心 | 通过t细胞疗法治疗cmv视网膜炎的方法 |
| JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
| MX2018013959A (es) | 2016-05-25 | 2019-08-22 | Council Queensland Inst Medical Res | Metodos para tratar enfermedad autoinmune usando celulas t alogenicas. |
| AU2017326173B2 (en) | 2016-09-16 | 2022-08-18 | Baylor College Of Medicine | Platform for activation and expansion of virus-specific T-cells |
| US20200172864A1 (en) | 2016-09-26 | 2020-06-04 | Tessa Therapeutics Ltd. | T Cell Expansion Method |
| WO2018232467A1 (en) | 2017-06-22 | 2018-12-27 | The Westmead Institute for Medical Research | Adoptive t cell therapy 2 |
| JP2020533688A (ja) | 2017-09-06 | 2020-11-19 | ナント ホールディングス アイピー，エルエルシー | Ｈｌａ組織照合およびそのための方法 |
| IL286629B2 (en) | 2019-03-25 | 2024-10-01 | Baylor College Medicine | Multi-respiratory virus antigen-specific t cells and methods of making and using the same therapeutically |
| TWI777160B (zh) | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| AU2020297019A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis B virus (HBV) vaccines |
| US20220257654A1 (en) | 2019-07-23 | 2022-08-18 | Baylor College Of Medicine | Antigen-specific t cell banks and methods of making and using the same therapeutically |
| MX2022001322A (es) | 2019-07-29 | 2022-05-24 | Baylor College Medicine | Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente. |
| AU2020333654A1 (en) | 2019-08-16 | 2022-03-17 | Baylor College Of Medicine | Third party virus-specific T cell compositions, and methods of making and using the same in anti-viral prophylaxis |
| US20230028788A1 (en) | 2019-12-23 | 2023-01-26 | Baylor College Of Medicine | T cell performance assay as a prognostic factor for clinical outcome |
| WO2021189084A1 (en) | 2020-03-20 | 2021-09-23 | Baylor College Of Medicine | Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections |
| EP3974029A1 (en) | 2020-09-25 | 2022-03-30 | Universidad Autónoma de Madrid | Memory t cells as adoptive cell therapy for viral infections |
| WO2023159088A1 (en) | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
-
2011
- 2011-12-12 GB GBGB1121308.9A patent/GB201121308D0/en not_active Ceased
-
2012
- 2012-12-12 JP JP2014546633A patent/JP6203745B2/ja active Active
- 2012-12-12 WO PCT/GB2012/053114 patent/WO2013088148A2/en not_active Ceased
- 2012-12-12 US US14/364,626 patent/US20140341951A1/en not_active Abandoned
- 2012-12-12 HK HK15103777.6A patent/HK1203219A1/xx unknown
- 2012-12-12 EP EP12815750.0A patent/EP2791163B2/en active Active
- 2012-12-12 US US14/364,621 patent/US20150044258A1/en not_active Abandoned
- 2012-12-12 AU AU2012351843A patent/AU2012351843B2/en not_active Ceased
- 2012-12-12 JP JP2014546634A patent/JP2015505852A/ja active Pending
- 2012-12-12 EP EP12816092.6A patent/EP2791323A2/en not_active Withdrawn
- 2012-12-12 WO PCT/GB2012/053113 patent/WO2013088147A1/en not_active Ceased
- 2012-12-12 ES ES12815750T patent/ES2626492T5/es active Active
- 2012-12-12 AU AU2012351842A patent/AU2012351842B2/en active Active
-
2015
- 2015-12-28 US US14/981,440 patent/US20160184361A1/en not_active Abandoned
-
2017
- 2017-07-06 JP JP2017132663A patent/JP6657145B2/ja active Active
-
2018
- 2018-06-22 US US16/016,305 patent/US11963979B2/en active Active
-
2019
- 2019-11-08 JP JP2019203285A patent/JP2020022505A/ja not_active Withdrawn
-
2022
- 2022-01-27 US US17/586,698 patent/US20220152111A1/en active Pending
- 2022-04-13 JP JP2022066435A patent/JP2022089916A/ja active Pending
-
2023
- 2023-10-17 JP JP2023179166A patent/JP2023174861A/ja not_active Withdrawn
-
2025
- 2025-10-17 US US19/361,743 patent/US20260042987A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020022505A5 (https=) | ||
| Juno et al. | Cytotoxic CD4 T cells—friend or foe during viral infection? | |
| US20220251509A1 (en) | Platform for activation and expansion of virus-specific t-cells | |
| US10351824B2 (en) | Process of expanding T cells | |
| US10927344B2 (en) | Semi-static cell culture | |
| US10772914B1 (en) | EBV-specific immune cells | |
| JP2015519890A5 (https=) | ||
| JP2014511704A5 (https=) | ||
| US20090324630A1 (en) | Fusion multiviral chimeric antigen | |
| JP2014511704A (ja) | Ｔ細胞のプライミングのための方法 | |
| WO2015191874A1 (en) | Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use | |
| CN109563483A (zh) | T细胞扩增 | |
| JP2012530500A (ja) | サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法 | |
| JP2021519069A5 (https=) | ||
| CN115087732B (zh) | 来自人T细胞来源的iPS细胞的细胞毒性T细胞 | |
| Muñoz et al. | Ex vivo expansion and lentiviral transduction of Macaca nemestrina CD4+ T cells | |
| Prockop et al. | Viral Cytotoxic T Lymphocytes (CTLs): From Bench to Bedside | |
| JPWO2019191314A5 (https=) | ||
| Ghaemi-Bafghi | Viral evasion and subversion mechanisms of the host immune system | |
| D'Amico et al. | Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia | |
| Wang et al. | The Past and the Future of VSTs | |
| CA2863557C (en) | Process of expanding t cells | |
| EP4722349A1 (en) | Pluripotent stem cell-derived cd4-positive t cells, method for production thereof, and use thereof | |
| KR20250158024A (ko) | Hpv 특이적 세포상해성 t 세포의 t 세포 수용체 또는 그 기능적 단편 | |
| TWI403332B (zh) | 生產免疫細胞之方法及誘發產生免疫作用細胞的方法 |